# A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

> **NCT02315534** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** BBI608
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02315534
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2018-10-09
- **Final completion:** 2019-06-24
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315534, "A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02315534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*